Sufferers who are obtaining cyclosporine, tacrolimus or other brokers to avoid graft-vs .-host disease write-up bone marrow transplant aren't suitable for this trial Experimental: Dose expansion_sub-population 2_higher dose of niraparib MTDs and/or applicant RP2Ds for elimusertib made use of together with niraparib at an increased fastened dose. Supplementary Figure seven https://alfredw963lhd0.blogozz.com/profile